MARKET

AXSM

AXSM

Axsome Therapeut
NASDAQ
237.33
-0.59
-0.25%
After Hours: 237.33 0 0.00% 18:30 06/25 EDT
OPEN
238.83
PREV CLOSE
237.92
HIGH
244.67
LOW
236.60
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
260.19
52 WEEK LOW
96.09
MARKET CAP
12.21B
P/E (TTM)
-63.4725
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AXSM last week (0615-0619)?
Weekly Report · 3d ago
Axsome Therapeutics Is Maintained at Buy by TD Cowen
Dow Jones · 06/17 14:03
TD Cowen Maintains Buy on Axsome Therapeutics, Raises Price Target to $300
Benzinga · 06/17 13:53
Axsome Therapeutics price target raised to $300 from $275 at TD Cowen
TipRanks · 06/17 12:26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Guardian Pharmacy Services, Inc. Class A (GRDN) and Alto Neuroscience, Inc. (ANRO)
TipRanks · 06/17 11:31
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Axsome Therapeutics (AXSM)
TipRanks · 06/17 09:50
Axsome to Present New Sleep Disorder Data at SLEEP 2026, To Highlight AXS-12 and Solriamfetol Data for Narcolepsy and OSA
Benzinga · 06/15 11:10
Axsome presents new Phase 3 ENCORE trial data for AXS-12 in narcolepsy with cataplexy at SLEEP 2026
PUBT · 06/15 11:01
More
About AXSM
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.

Webull offers Axsome Therapeutics Inc stock information, including NASDAQ: AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.